Literature DB >> 17488884

The burden of herpes zoster and postherpetic neuralgia in the United States.

Bethany A Weaver1.   

Abstract

Herpes zoster (shingles), a painful and disabling disease, affects an estimated 1 million individuals in the United States annually and results in significant morbidity, lost productivity, and diminished quality of life. Herpes zoster constitutes the reactivation of varicella-zoster virus (VZV), the same virus that causes chickenpox. After resolution of chickenpox, VZV remains dormant in dorsal root ganglia. Varicella-zoster-specific cell-mediated immunity wanes naturally with advancing age or earlier in the setting of an altered immune status, which can result in the reactivation of VZV as herpes zoster. The pain associated with the rash caused by herpes zoster is often described as burning, stabbing, itching, or aching. Postherpetic neuralgia, the most common complication of herpes zoster, occurs after the zoster rash has resolved, affecting up to a third of patients. Herpes zoster is associated with significant morbidity, especially in the elderly. Herpes zoster is both more common and more severe among older adults. In both acute herpes zoster and postherpetic neuralgia, pain is the primary cause of morbidity.

Entities:  

Mesh:

Year:  2007        PMID: 17488884

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  23 in total

1.  Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.

Authors:  Raymond C Tait; McKenzie Ferguson; Christopher M Herndon
Journal:  J Pain Manag Med       Date:  2017-01-30

2.  Presentation and management of herpes zoster (shingles) in the geriatric population.

Authors:  Kenneth R Cohen; Rebecca L Salbu; Jerry Frank; Igor Israel
Journal:  P T       Date:  2013-04

3.  Herpes zoster vaccine for the elderly: boosting immunity.

Authors:  Joel V Chua; Wilbur H Chen
Journal:  Aging health       Date:  2010-04-01

4.  Increased Health Care Resource Utilization and Costs Associated with Herpes Zoster Among Patients Aged ≥50 Years with Chronic Obstructive Pulmonary Disease in the United States.

Authors:  Parinaz Ghaswalla; Philippe Thompson-Leduc; Wendy Y Cheng; Colin Kunzweiler; Min-Jung Wang; Michael Bogart; Brandon J Patterson; Mei Sheng Duh; John Wojciehowski; Suna Park; Barbara P Yawn
Journal:  Chronic Obstr Pulm Dis       Date:  2021-10-28

5.  Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy.

Authors:  Antonino Parlato; Vincenzo Romano Spica; Massimo Ciccozzi; Francesca Farchi; Francesca Gallè; Valeria Di Onofrio; Elisabetta Franco; Giorgio Liguori
Journal:  BMC Public Health       Date:  2010-06-12       Impact factor: 3.295

6.  The epidemiology of varicella in school-aged Greek children before the implementation of universal vaccination.

Authors:  A Katsafadou; G Ferentinos; A Constantopoulos; V Papaevangelou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-16       Impact factor: 3.267

Review 7.  Vaccines for preventing herpes zoster in older adults.

Authors:  Anna M Z Gagliardi; Brenda N G Andriolo; Maria R Torloni; Bernardo G O Soares
Journal:  Cochrane Database Syst Rev       Date:  2016-03-03

8.  Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

Authors:  Kerry J Laing; Ronnie M Russell; Lichun Dong; D Scott Schmid; Michael Stern; Amalia Magaret; Jürgen G Haas; Christine Johnston; Anna Wald; David M Koelle
Journal:  J Infect Dis       Date:  2015-03-17       Impact factor: 5.226

9.  Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia.

Authors:  Srinivas Nalamachu; Matthew Wieman; Leah Bednarek; Surya Chitra
Journal:  Patient Prefer Adherence       Date:  2013-06-18       Impact factor: 2.711

10.  A case of rheumatoid arthritis presenting with postherpetic neuralgia and abdominal-wall pseudohernia.

Authors:  Hristo P Dobrev; Penka A Atanassova; Vladimir N Sirakov; Lilia G Zisova
Journal:  Rheumatol Int       Date:  2010-01-12       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.